Bu öğeden alıntı yapmak, öğeye bağlanmak için bu tanımlayıcıyı kullanınız: http://hdl.handle.net/11452/28261
Başlık: Anticancer effect of a novel palladium-saccharinate complex of terpyridine by inducing apoptosis on ehrlich ascites carcinoma (EAC) in balb-C mice
Yazarlar: İkitimur-Armutak, Elif İlkay
Sönmez, Kıvılcım
Akgün-Dar, Kadriye
Şennazlı, Gülbin
Kapucu, Ayşegül
Yiğit, Funda
Uludağ Üniversitesi/Fen-Edebiyat Fakültesi/Kimya Bölümü.
Uludağ Üniversitesi/Tıp Fakültesi/Tıbbi Biyokimya Anabilim Dalı.
0000-0003-4875-5472
0000-0002-2849-3332
Ulukaya, Engin
Yılmaz, Veysel Turan
K-5792-2018
L-7238-2018
6602927353
56441123900
Anahtar kelimeler: Oncology
Pd(II) complex
EAC
In vivo
Tumor
PCNA
Apoptosis
Biological evaluation
Crystal-structure
Cancer
P53
Expression
Mechanisms
Mutations
Yayın Tarihi: Mar-2015
Yayıncı: International Institute of Anticancer Research
Atıf: İkitimur-Armutak, E. İ. vd. (2015). "Anticancer effect of a novel palladium-saccharinate complex of terpyridine by inducing apoptosis on ehrlich ascites carcinoma (EAC) in balb-C mice". Anticancer Research, 35(3), 1491-1498.
Özet: Background/Aim: [Pd(sac)(terpy)](sac)•4H2O (sac=saccharinate and terpy=2,2′:6′,2-terpyridine) is newlysynthesized palladium(II) (Pd) complex. We investigated the antiproliferative and apoptotic effects of this complex on Ehrlich ascites carcinoma (EAC). Materials and Methods: EAC cells were administered to 33 Balb/c mice. Mice were divided randomly into four groups: control, cisplatin, Pd(II) complex and paclitaxel. Control group animals received 0.9% NaCl; other groups received treatments cisplatin, Pd(II) complex and paclitaxel on days 7 and 12. At day 14, animals were sacrificed. Expression of active caspase-3, p53 and proliferating cell nuclear antigen (PCNA) was investigated and apoptosis was evaluated by terminal deoxynucleotidyltransferase (TdT)-mediated nick-end labelling (TUNEL) technique. Results: Expression of p53 and PCNA were found to be decreased (p<0.0001), cells with active caspase-3 and TUNEL-positive cells were found to be increased (p<0.0001) in all treatment groups. Conclusion: Like cisplatin and paclitaxel, this Pd(II) complex has a strong anticancer activity against EAC by inducing apoptosis and suppressing proliferation in vivo.
URI: https://ar.iiarjournals.org/content/35/3/1491
http://hdl.handle.net/11452/28261
ISSN: 0250-7005
1791-7530
Koleksiyonlarda Görünür:PubMed
Scopus
Web of Science

Bu öğenin dosyaları:
Dosya Açıklama BoyutBiçim 
Yılmaz_Ulukaya_2015.pdf485.72 kBAdobe PDFKüçük resim
Göster/Aç


Bu öğe kapsamında lisanslı Creative Commons License Creative Commons